Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

In 2019, about 463 million people suffered from diabetes and over 2 million people lost their lives to its complications, including common cardiovascular complications such as heart attacks and strokes. We need to discover new ways to combat diabetes and its complications to improve the quality of life and prolong the survival of millions of patients.

High blood sugar is toxic for blood vessels and this toxic effect is believed to be responsible for the cardiovascular complications of diabetes, such as heart attacks and strokes. Insulin is a common treatment used to reduce blood sugar levels in people with diabetes – usually administered with an insulin pen or pump.

But much to scientists’ surprise, clinical trials have shown that insulin treatment doesn’t reduce the risk of heart attacks and strokes, even though it greatly reduces sugar in the bloodstream. This means that controlling blood sugar with insulin is not enough to prevent damage in the blood vessels of patients with diabetes. Why does this happen? What are we missing in this chain of events?

Read the full article on The Conversation website, written by Ioannis Akoumianakis and Charalambos Antoniades (Radcliffe Department of Medicine)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.